drug_type
RELEVANT_DRUG
intervention_type
cellular therapy (bispecific antibody–armed autologous PBMCs)
drug_description
Autologous cell-based immunotherapy consisting of a patient’s fresh peripheral blood mononuclear cells (primarily T cells) armed ex vivo with an anti-CD3 x anti-EGFR bispecific antibody; upon reinfusion, redirects and activates T-cell cytotoxicity against EGFR-expressing tumor cells.
nci_thesaurus_concept_id
C208368
nci_thesaurus_preferred_term
Autologous Anti-CD3/Anti-EGFR Bispecific Antibody Armed Peripheral Blood Mononuclear Cells
nci_thesaurus_definition
A preparation of autologous peripheral blood mononuclear cells (PBMCs) in which T-lymphocytes are coated with a bispecific antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor (EGFR; HER1; ErbB1) and the T-cell surface antigen CD3 and activated ex vivo, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, the autologous anti-CD3/anti-EGFR bispecific antibody armed PBMCs target, bind to and selectively cross-link CD3-expressing T-cells and EGFR-expressing tumor cells. This results in the activation of cytotoxic T-lymphocytes (CTLs) and selective cytotoxicity towards the EGFR-expressing tumor cells. EGFR, a receptor tyrosine kinase, is overexpressed on the surfaces of various tumor cell types.
drug_mesh_term
Peripheral Blood Mononuclear Cells
drug_category
CULTURED CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous PBMCs (primarily T cells) are armed ex vivo with an anti-CD3×anti-EGFR bispecific antibody. After reinfusion, the bispecific antibody bridges CD3 on T cells to EGFR on tumor cells, activating and redirecting cytotoxic T-cell activity to lyse EGFR-expressing cancer cells without genetic modification.
drug_name
EGFR FPBMC
nct_id_drug_ref
NCT06479239